<DOC>
	<DOC>NCT00693706</DOC>
	<brief_summary>The purpose of the study is to compare the safety of &amp; immune response to a single dose of GSK Biologicals' cell-culture based influenza vaccine 138842A with that of a US licensed, egg-based trivalent influenza vaccine [Fluarix] in healthy adults.</brief_summary>
	<brief_title>Safety and Immune Response Study of GSK Biologicals' Influenza Virus Vaccine 1388442A Compared With Fluarix</brief_title>
	<detailed_description />
	<mesh_term>Influenza, Human</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<criteria>Subjects who the investigator believes can and will comply with the requirements of the protocol A male or nonpregnant, nonlactating female between 18 and 49 years of age at the time of vaccination Access to a telephone for scheduled followup telephone contacts Ability to provide written informed consent Healthy subjects as established by medical history and physical examination before entering into the study If the subject is female, she must be of nonchildbearing potential, or if she is of childbearing potential, she must practice adequate contraception for 30 days prior to vaccination and continue such precautions for 2 months after receipt of the study vaccine. All women will have a pregnancy test on the day of vaccination. Use of any investigational or nonregistered product (drug or vaccine) other than the study vaccine within 30 days preceding the dose of study vaccine, or planned use during the study period Receipt of systemic glucocorticoids within 30 days of study enrollment Administration of immunosuppressant, cytotoxic, or other immunemodifying drugs (other than glucocorticoids) or irradiation within 6 months prior to study enrollment or planned administration during the study period Administration of immunoglobulins and/or blood products within 3 months prior to study enrollment or planned administration during the study period Previous vaccination against influenza (20072008 influenza season) History of anaphylactic or other allergic reaction to influenza vaccine, any other vaccine, or any vaccine component or excipient History of GuillainBarre Syndrome (GBS) Acute disease, febrile illness, or upper respiratory infection at screening. History of splenectomy Any confirmed or suspected, acquired, congenital, or hereditary immunodeficiency or immunosuppressive condition (including human immunodeficiency virus [HIV]) based on medical history and physical examination Acquired or congenital coagulation disorders or known thrombocytopenia Current treatment with warfarin or heparin derivatives Known use of an analgesic or antipyretic medication within 12 hours prior to treatment for the purposes of prophylaxis of adverse events Any medical condition for which the US Advisory Committee on Immunization Practices recommends vaccination against influenza</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>October 2016</verification_date>
	<keyword>cell culture</keyword>
	<keyword>Safety</keyword>
	<keyword>Influenza</keyword>
	<keyword>Humans</keyword>
	<keyword>Adults</keyword>
	<keyword>Immunogenicity</keyword>
	<keyword>Influenza vaccine</keyword>
	<keyword>Vaccine</keyword>
</DOC>